Risks of pelvic inflammatory disease and bacterial vaginosis in adenomyosis patients using levonorgestrel intrauterine device or oral norethindrone [PDF]
Frontiers in EndocrinologyBackgroundPatients with adenomyosis frequently experience menorrhagia and dysmenorrhea. Levonorgestrel-releasing intrauterine device (LNG-IUD) and oral norethindrone are widely used non-surgical treatment options.
Szu-Yun Niu +6 more
doaj +2 more sources
Suppression of an accessory and cavitated uterine mass with norethindrone: a case report [PDF]
F&S ReportsObjective: To describe conservative management for accessory and cavitated uterine mass (ACUM) with norethindrone acetate. The patient gave signed written, informed consent authorizing publication.
Hope Knochenhauer, M.D. +2 more
doaj +2 more sources
A Matched Case-Control Study Examining the Association Between Exposure to Depot Medroxyprogesterone Acetate and Cerebral Meningioma Using an Active Comparator [PDF]
Current OncologyThe recent literature has reported an increased association between the use of depot medroxyprogesterone acetate (dMPA) and cerebral meningioma (CM). Prior studies have been limited in generalizability and did not use an active comparator as a control ...
Russell Griffin, Rebecca Arend
doaj +2 more sources
Venous thromboembolism in obese hormonal contraceptive users: a large national database study [PDF]
Research and Practice in Thrombosis and HaemostasisObjectives: This study aimed to assess the risk of venous thromboembolism (VTE) among obese and nonobese females aged 10 to 44 years prescribed hormonal therapy (HT) and compare VTE rates between different HT types in a large national database.
Divyaswathi Citla-Sridhar +5 more
doaj +2 more sources
Scientific ReportsAbnormal uterine bleeding (AUB) represents a notable sign for benign and malignant uterine pathology. Differentiating adenomyosis from leiomyoma via hysteroscopy aids in selecting appropriate surgical or medical management.
Ahmed Ali +3 more
doaj +2 more sources
Norethindrone Acetate in the Medical Management of Adenomyosis
Pharmaceuticals, 2012 The role of norethindrone acetate (NA) in the management of adenomyosis was evaluated with a retrospective chart review of 28 premenopausal women between 27–49 years of age presenting with moderate to severe pelvic pain and bleeding.
Özgül Muneyyirci-Delale
exaly +3 more sources
Use of Oral Gonadotropin Releasing Hormone Antagonist Combinations for Preoperative Management of Refractory Leiomyoma-Related Heavy Menstrual Bleeding [PDF]
Women's Health ReportsUterine leiomyomas are noncancerous smooth muscle neoplasms that occur in up to 70% of women and the single most common cause of hysterectomy. There is a variety of treatments available for uterine leiomyomas, including medications, uterine artery ...
Danielle A. Aase, Elizabeth A. Stewart
doaj +2 more sources
International Journal of Women's HealthEssam R Othman,1,2 Ayman Al-Hendy,3 Radwa Mostafa,1 Cornelis B Lambalk,2 Velja Mijatovic2 1OB-GYN Department, Assiut University, Assiut, 71515, Egypt; 2Academic Endometriosis Center, Amsterdam University Medical Center, Vrije Universiteit Amsterdam ...
Velja Mijatović +2 more
exaly +2 more sources
Safety and efficacy of relugolix combination therapy in symptomatic uterine fibroids [PDF]
Facts, Views & Vision in ObGynBackground: Relugolix-combination therapy (CT) (oestradiol 1 mg and norethindrone acetate 0.5 mg) is a new gonadotropin-releasing hormone antagonist licensed to treat heavy menstrual bleeding (HMB) associated with uterine fibroids; but little real-world ...
Maria Chiara De Angelis +7 more
doaj +2 more sources